Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

A CD19-specific CAR T-cell therapy with intermediate affinity for CD19 produced a response in 77% of adults with refractory disease. Overall survival was 61% at 12 months, and serious toxic effects were rare.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology